What the PinCell acquisition option reveals about Scinai Immunotherapeutics’ pipeline strategy
Scinai Immunotherapeutics seeks €12M EU funding to advance PC111 for rare autoimmune skin diseases. Explore the clinical, regulatory, and industry implications.